Insights from 5-year data on olutasidenib for mutated IDH1 acute myeloid leukemia

In this interview, we sit down with Justin Watts (Sylvester Comprehensive Cancer Center, FL, USA) to discuss the results from the Phase II trial that led to the US FDA approval of olutasidenib for treating IDH1-mutated acute myeloid leukemia (AML). With 5-year follow-up data now available, Watts discusses the potential clinical implications for AML patients and future research directions. Can you provide us with an overview of your AML presentation at ASCO? Our study shows final 5-year follow-up data from the pivotal Phase II trial leading to olutasidenib’s FDA approval in 2023. View more details here >>> What are the...